文献速递青光眼白内障与屈光手术

微创青光眼手术技术治疗开角型青光眼:Cochrane系统综述概览与网状Meta分析

Minimally Invasive Glaucoma Surgical Techniques for Open-Angle Glaucoma: An Overview of Cochrane Systematic Reviews and Network Meta-analysis.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

该研究汇总了6篇Cochrane系统综述,评估微创青光眼手术(MIGS)治疗开角型青光眼的随机临床试验数据。中等确定性证据显示,在白内障手术基础上加用Hydrus或iStent可安全提高无滴眼液控制眼压的概率,但iStent的短期降眼压效果不持久;加用CyPass虽改善无滴眼液控制,但与视力丧失风险增加相关。

要点

  • Hydrus联合白内障手术在中远期显著提高无滴眼液控制且降眼压更优。
  • iStent联合白内障手术可安全提高无滴眼液控制,但短期降眼压不持久。
  • CyPass联合白内障手术改善无滴眼液控制,但视力丧失风险增加。

核心结论

  • 部分MIGS可为青光眼患者提供比单纯白内障手术更好的无滴眼液疾病控制。
  • 在现有产品中,随机临床试验数据表明Hydrus比iStent具有更好的无滴眼液控制和降眼压效果,但效应量较小。

研究设计与样本

  • 研究为Cochrane系统综述概览及网状Meta分析,检索Cochrane系统综述数据库至2021年6月1日。
  • 纳入比较MIGS与单纯白内障手术、其他MIGS、传统青光眼手术、激光小梁成形术或药物治疗的随机临床试验综述。
  • 共纳入6篇符合条件的Cochrane系统综述,涉及iStent或Hydrus微支架、Trabectome内路小梁切开术、结膜下和脉络膜上腔引流装置以及内镜下睫状体光凝术。

主要发现

  • 与单纯白内障手术相比,加用Hydrus在中远期(6-18个月)和长期(>18个月)随访中提高无滴眼液控制的可能性(中期RR 1.6,95%CI 1.4-1.8;长期RR 1.6,95%CI 1.4-1.9),长期眼压多降低2.0 mmHg(95%CI -2.7至-1.3 mmHg)。
  • 与单纯白内障手术相比,加用iStent提高无滴眼液疾病控制(RR 1.4,95%CI 1.2-1.6),但短期降眼压效果不持久。
  • 与单纯白内障手术相比,加用CyPass微支架改善无滴眼液青光眼控制(RR 1.3,95%CI 1.1-1.5),但与视力丧失风险增加相关。
  • 网状Meta分析支持上述结果的方向和幅度。

关键数值与推荐

  • 主要结局为术后无需使用降眼压药物的参与者比例(无滴眼液)。
  • 结局分析时间点为短期(<6个月)、中期(6-18个月)和长期(>18个月)。
  • 证据确定性采用AMSTAR 2工具评估,Hydrus相关证据为中等确定性。

临床怎么用

  • 对于开角型青光眼患者,在白内障手术时可考虑联合Hydrus或iStent以增加无滴眼液控制的可能性。
  • 选择MIGS产品时需权衡疗效与安全性,CyPass因视力丧失风险增加需谨慎使用。
  • iStent的短期降眼压效果不持久,临床决策时应考虑长期疾病控制需求。

局限性

  • 研究仅基于Cochrane系统综述中纳入的随机临床试验数据,可能受原始研究局限性的影响。
  • 原文未报告所纳入综述的具体样本量、发表偏倚评估等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Glaucoma affects more than 75 million people worldwide. Intraocular pressure (IOP)-lowering surgery is an important treatment for this disease. Interest in reducing surgical morbidity has led to the introduction of minimally invasive glaucoma surgeries (MIGS). Understanding the comparative effectiveness and safety of MIGS is necessary for clinicians and patients. OBJECTIVE: To summarize data from randomized clinical trials of MIGS for open-angle glaucoma, which were evaluated in a suite of Cochrane reviews. DATA SOURCES: The Cochrane Database of Systematic Reviews including studies published before June 1, 2021. STUDY SELECTION: Reviews of randomized clinical trials comparing MIGS with cataract extraction alone, other MIGS, traditional glaucoma surgery, laser trabeculoplasty, or medical therapy. DATA EXTRACTION AND SYNTHESIS: Data were extracted according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines by one investigator and confirmed by a second. Methodologic rigor was assessed using the AMSTAR 2 appraisal tool and random-effects network meta-analyses were conducted. MAIN OUTCOMES AND MEASURES: The proportion of participants who did not need to use medication to reduce intraocular pressure (IOP) postsurgery (drop-free). Outcomes were analyzed at short-term (<6 months), medium-term (6-18 months), and long-term (>18 months) follow-up. RESULTS: Six eligible Cochrane reviews were identified discussing trabecular bypass with iStent or Hydrus microstents, ab interno trabeculotomy with Trabectome, subconjunctival and supraciliary drainage devices, and endoscopic cyclophotocoagulation. Moderate certainty evidence indicated that adding a Hydrus safely improved the likelihood of drop-free glaucoma control at medium-term (relative risk [RR], 1.6; 95% CI, 1.4 to 1.8) and long-term (RR, 1.6; 95% CI, 1.4 to 1.9) follow-up and conferred 2.0-mm Hg (95% CI, -2.7 to -1.3 mm Hg) greater IOP reduction at long-term follow-up, compared with cataract surgery alone. Adding an iStent also safely improved drop-free disease control compared with cataract surgery alone (RR, 1.4; 95% CI, 1.2 to 1.6), but the short-term IOP-lowering effect of the iStent was not sustained. Addition of a CyPass microstent improved drop-free glaucoma control compared with cataract surgery alone (RR, 1.3; 95% CI, 1.1 to 1.5) but was associated with an increased risk of vraision loss. Network meta-analyses supported the direction and magnitude of these results. CONCLUSIONS AND RELEVANCE: Based on data synthesized in Cochrane reviews, some MIGS may afford patients with glaucoma greater drop-free disease control than cataract surgery alone. Among the products currently available, randomized clinical trial data associate the Hydrus with greater drop-free glaucoma control and IOP lowering than the iStent; however, these effect sizes were small.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bicket AK, Le JT, Azuara-Blanco A, et al. Minimally Invasive Glaucoma Surgical Techniques for Open-Angle Glaucoma: An Overview of Cochrane Systematic Reviews and Network Meta-analysis. JAMA Ophthalmol. 2021. PMID: 34264292. doi:10.1001/jamaophthalmol.2021.2351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。